Studies confirm non-inferiority of doravirine / islatravir to standard HIV treatment
Top 5 stories on injectable HIV treatment and PrEP from CROI 2024
Top 5 HIV treatment stories from CROI 2024
Islatravir plus lenacapavir could be the first once-weekly oral HIV treatment
Broadly neutralising antibodies may be partners for long-acting antiretrovirals
Once-weekly antiretrovirals on the horizon
If one antibody won’t work, how about three? Or three in one?
New HIV drugs should be classed as inferior if they carry a higher risk of resistance
Long-acting injectable version of the most popular HIV drug combination is possible
